Genetics

Intellia Therapeutics released its financial results for the second quarter of 2017.

Intellia Therapeutics (NASDAQ:NTLA) released its financial results for the second quarter of 2017.
As quoted in the press release:

The company has made significant progress using our proprietary lipid nanoparticle (LNP) delivery system throughout the quarter. We advanced into non-human primate studies, while first time data from rat studies, the second species we tested in vivo, confirmed the durable mouse data demonstrating high levels of sustained genome editing and serum transthyretin (TTR) reduction post-single-dose intravenous administration.
“We are very excited that our initial non-human primate data in vivo continue to validate our mRNA delivery technology. These preclinical data accelerate our momentum as we advance the development of potential therapies to treat patients with high unmet medical needs,” said Chief Executive Officer and founder Nessan Bermingham, Ph.D., Intellia Therapeutics. “During the quarter, we have further strengthened our company by advancing partnerships, including a research agreement with Ospedale San Raffaele in Milan for our ex vivo technology focused on novel engineered cell therapies using CRISPR, expanded our global intellectual property portfolio, and appointed two new members to our Board of Directors.”

Click here to read the full press release.

Source: globenewswire.com

Featured

MARKETS

Markets
TSX21274.57-262.88
TSXV890.86-18.85
DOW35368.47-543.34
S&P 5004577.11-85.74
NASD14506.90-386.86
ASX7417.30+23.40

COMMODITIES

Commodities
Gold1812.89-1.18
Silver23.44-0.01
Copper4.40+0.02
Palladium1897.50+11.50
Platinum982.00+1.00
Oil86.74+1.31
Heating Oil2.66+0.04
Natural Gas4.36+0.08

DOWNLOAD FREE REPORTS

×